Correction to: Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study.
作者信息
Paunescu Alexandra-Cristina, Copie Bergman Christiane, Malak Sandra, Le Gouill Steven, Ribrag Vincent, Bouabdallah Krimo, Sibon David, Rumpold Gerhard, Preau Marie, Mounier Nicolas, Haioun Corinne, Jardin Fabrice, Besson Caroline
机构信息
Inserm CESP U1018, Gustave Roussy, 114 Rue Edouard Vaillant, 94805, Villejuif, France.
Department of Pathology, CHU Henri Mondor, AP-HP, Paris, France.
出版信息
Ann Hematol. 2022 Feb;101(2):333. doi: 10.1007/s00277-021-04705-7.
Abstract
摘要
相似文献
1
Correction to: Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study.
Ann Hematol. 2022 Feb;101(2):333. doi: 10.1007/s00277-021-04705-7.
2
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
J Clin Oncol. 2018 Jun 1;36(16):1603-1610. doi: 10.1200/JCO.2017.76.5198. Epub 2018 Apr 19.
3
Consolidation anti-CD22 fractionated radioimmunotherapy with Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial.
Lancet Haematol. 2017 Jan;4(1):e35-e45. doi: 10.1016/S2352-3026(16)30168-5. Epub 2016 Dec 8.
4
Quality of life and related demographic factors in long-term survivors of childhood non-Hodgkin's lymphoma.
Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(9):882-888. doi: 10.7499/j.issn.1008-8830.2106035.
5
Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry.
Ann Hematol. 2014 May;93(5):811-9. doi: 10.1007/s00277-013-1980-1. Epub 2013 Dec 8.
6
Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA.
Am J Surg Pathol. 2019 Mar;43(3):341-351. doi: 10.1097/PAS.0000000000001198.
7
Late Neurological and Cognitive Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi.
Cancers (Basel). 2021 Jul 7;13(14):3401. doi: 10.3390/cancers13143401.
8
Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.
Cancer Med. 2018 Mar;7(3):539-548. doi: 10.1002/cam4.1139. Epub 2018 Feb 23.
9
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.
Future Oncol. 2021 Apr;17(11):1295-1310. doi: 10.2217/fon-2020-0946. Epub 2021 Feb 2.
10
Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies.
Leuk Lymphoma. 2016 Dec;57(12):2820-2826. doi: 10.1080/10428194.2016.1177180. Epub 2016 Apr 27.
引用本文的文献
1
Impact of comorbidity on health-related quality of life in newly diagnosed patients with lymphoma or multiple myeloma: results from the PROFILES-registry.
Ann Hematol. 2024 Dec;103(12):5511-5525. doi: 10.1007/s00277-024-06006-1. Epub 2024 Sep 16.
2
Patients' experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study.
Support Care Cancer. 2023 Apr 26;31(5):303. doi: 10.1007/s00520-023-07763-x.
Zotero 插件